Combination therapies of chimeric antigen receptors and PD-1 inhibitors
Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., CD19, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., CD19, in combination with a PD- Iinhibitor..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 22. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ANAK OEZLEM [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-22, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
AU2023284778 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019341520 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019341520 | ||
| 003 | DE-627 | ||
| 005 | 20240308101627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019341520 | ||
| 035 | |a (EPA)AU2023284778 | ||
| 035 | |a (EPA)59700172 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ANAK OEZLEM |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-22, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-08 | ||
| 520 | |a Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., CD19, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., CD19, in combination with a PD- Iinhibitor. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a BILIC SANELA |4 aut | |
| 700 | 0 | |a BROGDON JENNIFER |4 aut | |
| 700 | 0 | |a CAMERON JOHN SCOTT |4 aut | |
| 700 | 0 | |a CHOU WILLIAM |4 aut | |
| 700 | 0 | |a HOWARD DANNY ROLAND JR |4 aut | |
| 700 | 0 | |a ISAACS RANDI |4 aut | |
| 700 | 0 | |a JUNE CARL H |4 aut | |
| 700 | 0 | |a LACEY SIMON |4 aut | |
| 700 | 0 | |a MAUDE SHANNON |4 aut | |
| 700 | 0 | |a MELENHORST JAN J |4 aut | |
| 700 | 0 | |a SCHUSTER STEPHEN |4 aut | |
| 700 | 0 | |a QUINTAS-CARDAMA ALFONSO |4 aut | |
| 700 | 0 | |a GRUPP STEPHAN |4 aut | |
| 700 | 0 | |a BITTER HANS |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 22. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:22 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/59700172/publication/AU2023284778A1?q=AU2023284778 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 22 |c 02 | ||